Sedia Biosciences Announces Global Launch of New Research Assay to Detect Recent HIV-1 Infections
The Sedia™ HIV-1 Limiting Antigen Avidity Enzyme Immunoassay, a powerful new tool in the global fight against HIV, measures the maturation of the immune response to identify recent HIV infections among those already identified as positive.
By: Sedia Biosciences Corporation
The Sedia™ HIV-1 LAg-Avidity EIA uses technology developed by and licensed from the U.S. Centers for Disease Control and Prevention (“CDC”) and commercialized by Sedia. Sedia’
The CDC and Sedia have collaborated in the development of the assay, and each lot manufactured by Sedia is tested and approved by the CDC prior to release. Sedia is the only manufacturer that sells CDC approved assay kits. Steve Piacentini, Sedia’s Director of Assay Development, commented on the product design: “The Sedia™ HIV-1 LAg-Avidity EIA is a uniquely designed 2 hour assay that uses a more efficient single well assay system, instead of conventional ‘two-well avidity assays’. It incorporates a multi-clade protein marker (antigen) representing the major HIV-1 subtypes to ensure good cross-reactivity among HIV-1 subtypes, and uses assay plates subdividable down to individual wells to maximize efficient use of the assay.” Sedia, the market leader in HIV incidence assays, also manufactures and supplies the HIV-1 BED Incidence Assay which measures HIV-1 incidence based on alternative antibody ratio principles licensed from the CDC and was first commercialized by the same scientists who have developed the Sedia™ HIV-1 LAg-Avidity EIA at Sedia. Additional information about both assays is available at http://www.hivincidence.com.
Sedia is also developing the assay to enable testing of dried blood spot specimens, often the specimen of choice in resource-constrained developing countries, and is further developing the assay for individual diagnostic use to enable targeted intervention and case management of individual recent infections, which will require FDA approval.
Research reported in this press release was supported by a Small Business Innovation Research grant from the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R43AI097001. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.